ABSTRACT
Objective: To explore the effect of β-blocker in hypertension patients with different basic heart rate (HR). Methods: A total of 191 hypertension patients without using β-blocker were enrolled. Based on different basic HR, the patients were divided into 3 groups: Group A: HR (70-79) beats/min, n=58, Group B: HR (80-89) beats/min, n=90 and Group C: HR≥90 beats/min, n=43. All patients received metoprolol extended release at 47.5 mg/d for 2 weeks, for those didn't reach the target HR, 23.75 mg/d was added as 71.25 mg/d for 4 weeks, for those still didn't reach target HR, the dose was added to 95 mg/d, total length of medication was 8 weeks. Blood pressure (BP) and HR were measured every 2 weeks in all patients. Results: 62％ patients had basic HR>80 beats/min, 36％ had basic HR>85 beats/min and 20％ had basic HR>90 beats/min. The average dose of metoprolol was (59.7±17.0) mg/d. HR decreased in 3 groups after medication, all P<0.05. The reducing level in Group C was (29.3±7.8) beats/min, in Group B was (18.7±4.9) beats/min and in Group A was (11.0±4.0) beats/min, P<0.05; upon HR elevating 10 beats/minute, metoprolol caused HR reducing may increase 7.9％. BP was similar among 3 groups before and after medication, P>0.05. The average HR decreasing levels in patients with metoprolol 47.5 mg/d, 71.25 mg/d and 95 mg/d were (17.6±8.1) beats/min, (19.5±8.7) beats/min and (22.5±9.2) beats/min respectively; upon dose elevated to 71.25 mg/d and 95 mg/d, metoprolol caused HR reducing may increase10.8％ and 27.8％. 1 patient had sinus bradycardia and 1 had dizziness during medication, the symptoms improved by dose reducing or drug withdrawal.Conclusion: About 2/3 hypertension patients had basic HR>80 beats/min, metoprolol could cause more HR reducing in patients with the faster basic HR. Metoprolol (47.5-95) mg/d was safe and effective in hypertension patients.
ABSTRACT
Objective: To explore the effect of β-blocker in hypertension patients with different basic heart rate (HR). Methods: A total of 191 hypertension patients without using β-blocker were enrolled. Based on different basic HR, the patients were divided into 3 groups: Group A: HR (70-79) beats/min, n=58, Group B: HR (80-89) beats/min, n=90 and Group C: HR≥90 beats/min, n=43. All patients received metoprolol extended release at 47.5 mg/d for 2 weeks, for those didn't reach the target HR, 23.75 mg/d was added as 71.25 mg/d for 4 weeks, for those still didn't reach target HR, the dose was added to 95 mg/d, total length of medication was 8 weeks. Blood pressure (BP) and HR were measured every 2 weeks in all patients. Results: 62％ patients had basic HR>80 beats/min, 36％ had basic HR>85 beats/min and 20％ had basic HR>90 beats/min. The average dose of metoprolol was (59.7±17.0) mg/d. HR decreased in 3 groups after medication, all P<0.05. The reducing level in Group C was (29.3±7.8) beats/min, in Group B was (18.7±4.9) beats/min and in Group A was (11.0±4.0) beats/min, P<0.05; upon HR elevating 10 beats/minute, metoprolol caused HR reducing may increase 7.9％. BP was similar among 3 groups before and after medication, P>0.05. The average HR decreasing levels in patients with metoprolol 47.5 mg/d, 71.25 mg/d and 95 mg/d were (17.6±8.1) beats/min, (19.5±8.7) beats/min and (22.5±9.2) beats/min respectively; upon dose elevated to 71.25 mg/d and 95 mg/d, metoprolol caused HR reducing may increase10.8％ and 27.8％. 1 patient had sinus bradycardia and 1 had dizziness during medication, the symptoms improved by dose reducing or drug withdrawal.Conclusion: About 2/3 hypertension patients had basic HR>80 beats/min, metoprolol could cause more HR reducing in patients with the faster basic HR. Metoprolol (47.5-95) mg/d was safe and effective in hypertension patients.